Sanofi Eyes First On-Body Injector Cancer Therapy As FDA Delays Decision

All NewsApril 22, 2026

Sanofi says FDA delays Sarclisa SC review to July while expanding Tzield use to younger children with type 1 diabetes.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent